AHA statement before the Senate Committee on Health, Education, Labor and Pensions: Hearing on How to Reduce Health Care Costs: Understanding the Cost of Health Care in America”
Testimony
Every day, AHA staff take to Capitol Hill to tell the hospital story, working to educate Congress on key issues and the field’s concerns. We also advocate with federal regulators, provide expert testimony, and highlight the impact proposed changes could have and suggest alternative solutions. Below are the most recent statements the AHA has submitted for the record for congressional hearings or agency panels.
Latest
AHA statement before the Senate Finance Committee on Prescription Drug Affordability and Innovation: Addressing Challenges in Today’s Market.
AHA Statement before the Senate Committee on Health, Education, Labor and Pensions regarding “Effective Administration of the 340B Drug Pricing Program.”
AHA Statement to the Committee on Ways and Means for “Hearing on Lowering Costs and Expanding Access to Health Care through Consumer-Directed Health Plans.”
AHA statement before the Senate Finance Committee on "Rural Health Care in America: Challenges and Opportunities."
AHA Statement before the Senate Committee on Health, Education, Labor and Pensions: Examining Oversight Reports on the 340B Drug Pricing Program
AHA expresses strong support for legislation that would allow responsible sharing of patient substance use disorder (SUD) treatment information and prevent inappropriate
AHA submit statement before the House Ways and Means Subcommittee on Health.regarding innovative practices and technology in health care.
AHA statement before the House Homeland Security Committee on emergency preparedness and lessons learned from Hurricane Harvey.
Statement of the American Hospital Association before the Subcommittee on Health of the Committee on Ways and Means of the U.S. House of Representatives on Alternative Payment Models (APMs) in the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA) on March 21, 2018.
AHA Statement before the Senate Committee on Health, Education, Labor and Pensions Re: Perspectives on the 340B Drug Pricing Program